Western and Sumagen to release preliminary results from HIV/AIDS vaccine trials
Monday, November 5, 2012
WHAT: Western
University and Sumagen Canada will hold a briefing for media and
London's research community regarding preliminary results for the
first-ever human applied clinical study (SAV CT 01) of the world's only
preventative HIV vaccine based on a genetically modified killed whole
virus (SAV001-H), which was initiated in March 2012.
Last year, SAV001-H received approval by the United States Food and Drug Administration (FDA) to start human clinical trials.
http://communications.uwo.ca/media/hivvaccine/
WHEN: Tuesday, November 6, 2012 at 11 a.m.
WHERE: Siebens Drake Research Institute, Room 217, Western University, London, Ontario
WHO: Dr. Chil-Yong Kang of Western's Schulich School of Medicine & Dentistry and Dr. Dong Joon Kim of Sumagen Co. Ltd.
Media is advised parking is available at Dental Parking Lot (C) and Social Science Lot (J).
http://www.uwo.ca/parking/parkingmap.pdf
MEDIA CONTACT: Jeff Renaud, Senior Media Relations Officer, 519-661-2111, ext. 85165, jrenaud9@uwo.ca
http://communications.uwo.ca/media/hivvaccine/
WHEN: Tuesday, November 6, 2012 at 11 a.m.
WHERE: Siebens Drake Research Institute, Room 217, Western University, London, Ontario
WHO: Dr. Chil-Yong Kang of Western's Schulich School of Medicine & Dentistry and Dr. Dong Joon Kim of Sumagen Co. Ltd.
Media is advised parking is available at Dental Parking Lot (C) and Social Science Lot (J).
http://www.uwo.ca/parking/parkingmap.pdf
MEDIA CONTACT: Jeff Renaud, Senior Media Relations Officer, 519-661-2111, ext. 85165, jrenaud9@uwo.ca
Media Releases Feed
